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Proximity-dependent biotin identification (BioID) is a recently developed method that allows
the identification of proteins in the close vicinity of a protein of interest in living cells. BioID
relies on fusion of the protein of interest with a mutant form of the biotin ligase enzyme BirA
(BirA*) that is capable of promiscuously biotinylating proximal proteins irrespective of whether
these interact directly or indirectly with the fusion protein or are merely located in the same
subcellular neighborhood. The covalent addition of biotin allows the labeled proteins to be
purified from cell extracts on the basis of their affinity for streptavidin and identified by mass
spectrometry. To date, BioID has been successfully applied to study a variety of proteins and
processes inmammalian cells and unicellular eukaryotes and has been shown to be particularly
suited to the study of insoluble or inaccessible cellular structures and for detecting weak or
transient protein associations. Here, we provide an introduction to BioID, together with a
detailed summary of where and how the method has been applied to date, and briefly discuss
technical aspects involved in the planning and execution of a BioID study.
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1 Introduction
Building comprehensive protein interactome maps is key
to understanding cell function. A particular challenge is
in building maps that account not only for direct bi-
nary protein–protein interactions, but also which incorpo-
rate information on indirect interactions (for example, be-
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tween proteins that do not interact directly with one an-
other, but which are components of the same multipro-
tein complex) and proximal protein networks. Interactome
discovery methods also need to take into account the dy-
namic nature of many cellular processes and overcome
the technical challenges posed by weak protein–protein
interactions.
Proximity-dependent labeling by modifying enzymes [1,2]
is a novel approach for protein–protein interaction screening
that addresses these challenges. When fused to the protein
of interest the modifying enzymes covalently attach a tag
on proximal and potentially interacting proteins, which al-
lows their subsequent purification and identification by MS.
Examples of such techniques include selective proteomic
proximity labeling using tyramide [3], ascorbate peroxidase
(APEX) [4, 5], and proximity-dependent biotin identification
(BioID) [6]. Here we focus on BioID, which is already making
a major impact on our understanding of cell structure and
function [7]. BioID offers significant advantages over conven-
tional interactome discovery methods, particularly in regards
to the identification of transient or weak interactions but also
through its applicability to insoluble subcellular structures.
The BioID technique makes use of the ability of a mutant
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Figure 1. BioID. The protein of interest is fused with a promiscuous form (BirA*) of the bacterial biotin ligase BirA and expressed in cells.
In the figure, the target protein (pale orange) has an elongated structure and BirA* (red) is shown fused to the N-terminal end (C-terminal
fusion is also possible). BirA* converts exogenously added free biotin to highly reactive but labile biotinyl-5′-AMP (yellow) which is released
from the enzyme’s active site allowing it to react with primary amines on proximal proteins (blue, green), irrespective of whether they
interact (directly or indirectly via additional protein–protein interactions) with the fusion protein or are merely in the close vicinity (labeling
radius 10 nm, based on studies of the NPC Y-complex, see text for details). Distal proteins (gray), whether they interact with the BirA*
fusion or not, are not labeled. In the example shown, with the BirA* enzyme fused to the N-terminal end of the protein of interest, note how
factors that interact at the C-terminal end of the protein are not labeled, as they lie beyond the effective labeling radius. Following biotin
labeling, cells are lysed and proteins extracted under relatively harsh conditions. Biotinylated proteins are then purified using streptavidin
(nonbiotinylated proteins are discarded) and identified by MS. See text for details and references.
form of the Escherichia coli biotin ligase (BirA*) to promis-
cuously biotinylate proximal proteins [6]. Biotin ligases are
highly conserved and biologically important enzymes that fa-
cilitate the attachment of biotin to their target proteins [8].
The well-characterized wild-type biotin ligase from E. coli
has a single protein target, a subunit of acetyl-CoA carboxy-
lase. Biotinylation is a two-step reaction, where the biotin
ligase uses biotin and ATP (adenosine triphosphate) to gener-
ate a highly reactive biotinoyl-5′-AMP (adenosine monophos-
phate) intermediate [9], which later reacts with a specific ly-
sine on the target protein to form an amide bond between
biotin and the lysine side chain, releasing AMP [8]. The
wild-type biotin ligase has high affinity for the biotinoyl-
5′-AMP intermediate, which remains within the active site
until the enzyme recognizes its acetyl-CoA carboxylase sub-
strate. In contrast, the mutant form of E. coli biotin ligase
BirA*, which carries R118G mutation at the active site, has
significantly reduced affinity for biotinoyl-5′-AMP and re-
leases it prematurely [10, 11]. In this way, the highly reac-
tive biotinoyl-5′-AMP can react with accessible lysine side
chains on the surrounding proteins in a proximity-dependent
manner, leaving the proteins covalently marked with biotin.
This promiscuous covalent labeling of proximal proteins with
biotin forms the basis of BioID method (Fig. 1) [6]. In a
typical BioID experiment, a gene fusion encoding the pro-
tein of interest and BirA* is expressed in vivo. Once
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synthesized, the protein of interest therefore carries the
BirA* tag (35.4 kDa) on either its N- or C-terminus. Bi-
otin is then added and after a suitable incubation pe-
riod (typically 24 h) the cells are harvested, proteins ex-
tracted, and biotinylated proteins purified using strep-
tavidin. MS is then used to identify the biotinylated
proteins.
As labeling is proximity-dependent, potential interactors of
the protein of interest must reside within the area reachable
by the reactive biotinoyl-5′-AMP. This area can be described
as the practical labeling radius of BirA*. Initial studies by
Roux et al. [6] suggested the radius to be approximately 20–
30 nm. This was later reduced to10 nm by using the known
structure of the nuclear pore complex (NPC) as a “molecular
ruler” [12]. Although the exact value may vary depending on
the protein complex under study, this radius is sufficient to
allow detection of both direct interactors and noninteracting
vicinal proteins.
BioID has several key advantages overmore established in-
teractome discovery methods [6]. First, it is important to em-
phasize that while the biotin labeling is proximity-dependent,
it does not require either direct or indirect protein–protein
interaction between the BirA* fusion and the protein that
becomes biotinylated (illustrated in Fig. 1). Noninteracting
but proximal proteins are also labeled, giving valuable infor-
mation on the proteomic landscape surrounding the target.
Second, proteins that transiently interact with—or are tran-
siently proximal to—the BirA* fusion will also be biotinylated
and, crucially, the biotinylation mark will remain even after
the interaction has ceased or the protein has moved out of
the vicinity of the BirA* fusion (Fig. 1). BioID is therefore
well suited to studying cellular processes that are dynamic
in space and time. Third, unlike more conventional meth-
ods such as affinity purification, where stringent extraction
conditions will disrupt protein–protein interactions and re-
sult in data loss, in BioID cell lysis and subsequent isolation
of biotinylated proteins via streptavidin binding can be per-
formed under stringent conditions. For this reason, BioID
is proving particularly useful for investigation of insoluble
proteins structures such as nuclear lamina or centrosome.
Finally, the only requirement for BioID is expression of a
correctly localized BirA* fusion protein. It is not absolutely
essential that the fusion protein is expressed at an appro-
priate level (comparable to the endogenous target protein)
or is functional, although as discussed below (see Section 5)
there may be advantages to ensuring that these conditions
are met.
While proximity-dependent labeling techniques have been
reviewed in the past [1,7], here we focus exclusively on BioID.
We provide a comprehensive summary of how the method
has been used tomap local interactomes in a variety of cellular
processes, both in mammals and in unicellular eukaryotes,
before discussing technical aspects involved in the planning
and execution of a BioID study and looking ahead to future
developments.
2 Application of BioID in mammalian
cells
2.1 Nuclear lamina
BioID was first introduced in 2012 in a landmark paper by
Roux et al. [6] reporting the application of the method to
the lamin A (LaA) protein, a key constituent of the nuclear
lamina, the filamentous protein network that underlies the
inner nuclear membrane (INM) [13]. The lamina is made up
of lamins (both A- and B-types) and nuclear lamin-associated
membrane proteins, such as LAP1 (lamin-associated polypep-
tide 1), LAP2, and emerin, and acts as an anchor for NPCs
that span the nuclear envelope (NE). Lamins are intermediate
filament proteins [14] and are highly insoluble, making them
largely intractable to conventional methods for screening for
protein–protein interactions and thus an ideal system to test
the effectiveness of the BioID concept.
To apply BioID to LaA, Roux et al. [6] generated HEK293
cells that stably and inducibly expressed aMyc-epitope tagged
BirA*-LaA fusion protein. Like the endogenous LaA, the fu-
sion localizes predominantly to the NE but with a subpopula-
tion present throughout the nucleus, indicating that addition
of theMyc-BirA*moiety to theN-terminus of the LaA protein
does not perturb its localization, an important precondition
for BioID. Following addition of 50 M biotin to the cul-
ture medium for 24 h, Myc-BirA*-LaA expressing cells were
lysed and proteins extracted under denaturing conditions,
with parental HEK293 cells being processed in parallel. Bi-
otinylated proteins were then captured using streptavidin and
subjected to MS.
Over 120 proteins were identified as being proximal to
the Myc-BirA*-LaA fusion in this study, including a number
of previously characterized NE components, including the
known lamin interactors LAP1, LAP2, emerin, and MAN1
[14]. Twelve proteins associated with nuclear-cytoplasmic
transport were also detected, including the NPC components
Nup50, Nup153, and ELYS [15]. A previously uncharacterized
protein FAM169A (later renamed SLAP75) was also identi-
fied and was shown to be a novel NE constituent by im-
munofluorescence microscopy, elegantly demonstrating the
power of the BioID approach for identifying novel proteins
[6]. A further ten uncharacterized proteins were also identi-
fied in this screen: whether these, like FAM169A/SLAP75,
will also be constituents of the NE remains to be
seen.
In a second study focused on the nuclear lamina, Dressen
and colleagues [16] used BioID to compare the interac-
tomes of LaA and progerin, a truncated form of the LaA
protein that is responsible for the progressive aging syn-
drome Hutchinson–Gilford progeria. While the two inter-
actomes displayed considerable overlap, in experiments per-
formed in both primary fibroblasts and pluripotent ES cells,
significantly less LAP2 was biotinylated by Myc-BirA*-
progerin compared to the full-length Myc-BirA*-LaA,
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suggesting a possible mechanism for how the LaA trunca-
tion causes Hutchinson–Gilford progeria [16].
More recently, BioID has also been used to generate an in-
teractome for lamin B1 (LMNB1). In these experiments [17]
LMNB1 was expressed as a Myc-MirA*-LMNB1 fusion from
a lentiviral vector in the mouse hepatocyte cell line AML12.
Over 180 potential interactors were identified in this screen,
including LaA, MAN1, LAP2 and, unexpectedly, the variant
histone macroH2A1 (mH2A1) previously shown to be asso-
ciated with repressive chromatin. Reciprocol BioID using a
Myc-BirA*-mH2A1 fusion led to biotinylation LMNB1, con-
firming the spatial proximity of these factors.
2.2 Nuclear pore complex
Embedded in the NE, the NPC allows bidirectional trans-
port of molecules (RNA, proteins, carbohydrates, signaling
molecules, and lipids) between the nucleus and cytoplasm.
The NPC is an extremely stable macromolecular structure
consisting of multiple copies of 30 different proteins and
with a molecular mass of 125 MDa [15].
In a second landmark paper [12], Roux and colleagues used
the NPC as a model system to probe the limits of the BioID
method in analyzing the architecture of large multiprotein
complexes, in particular to determine the effective labeling
radius of the BirA* enzyme. To achieve this, BioID was
performed on components of two NPC subcomplexes, the
Y-complex (also known as the Nup107–160 complex) and the
Nup93 complex. The Y-complex is extremely stable and has
an elongated Y-shaped structure, 40 nm long and 20 nmwide,
onto which individual subunits have been mapped by a vari-
ety of approaches [18]. This allowed the Y-complex to be used
as a "molecular ruler" by Kim et al. [12] who placed the BirA*
moiety at different defined locations on the complex, mea-
sured the extent of biotinylation of the other subunits and
correlated this with distance.
For this work, HEK293 cells constitutively expressing five
Y-complex components as BirA* fusions were constructed:
four proteins (Nup85, Nup107, Nup133, and Nup160)
were N-terminally tagged with Myc-BirA* and one (Nup43)
C-terminally tagged with BirA*-HA [12]. For analysis of the
Nup93 complex, a strain expressing a Myc-BirA*-Nup53 fu-
sion was created. In each case, care was taken to identify
clones expressing low levels of fusion protein, to prevent po-
tential complications caused by high levels of mislocalized
proteins. Prior to biotin labeling and further analysis, im-
munofluorescence microscopy was used to confirm that the
fusion proteins largely localized with NPCs. Identification of
biotinylated proteins revealed that most were known NPC
components. Importantly, the Y-complex and Nup53 fusions
labeled largely nonoverlapping sets of proteins, indicative of
the spatial specificity of BioID, with the Y-complex fusions
identifying other Y-complex components and the Nup53
fusion labeling other components of the Nup93 complex
and its near neighbors. By analyzing the results obtained in
relation to the subunit structure of the Y-complex, Roux and
colleagues [12] estimate the practical labeling radius in their
experiments to be10 nm, with labeling efficiency being sig-
nificantly reduced beyond this distance. Whether this value
is applicable more generally (i.e. beyond the Y-complex) re-
mains to be seen. It should also be noted that a lack of suitably
positioned lysine side chains may mean that proteins within
the practical labeling radius remain unlabeled and that nega-
tive results should therefore be treatedwith caution. Likewise,
a lack of suitably positioned lysine side chains in proteins fur-
ther from BirA* many mean that the 10 nm estimate for the
Y-complex is an underestimate.
2.3 Centrosome and centrosome-cilium interface
The centrosome is the principal microtubule organizing cen-
ter in animal cells and comprises two cylindrical centrioles
surrounded by an amorphousmass of pericentriolar material
(PCM) [19]. In addition to coordinating microtubule organi-
zation, centrioles also act as cilial basal bodies. Three sepa-
rate studies have now appeared describing the application of
BioID to probe the protein composition of the mammalian
centrosome and the centrosome-cilium interface [20–22].
Initially, Pelletier and colleagues [22] performed BioID
with a Flag-BirA*-CEP120 fusion protein stably and inducibly
expressed in HEK293 cells. CEP120 has an important role in
centriole biogenesis and BioID identified a range of known
centrosomal proteins proximal to it, including SPICE1 and
CPAP (whose interactions with CEP120 formed the main fo-
cus of the study) as well as CEP55, CEP95, CEP97, CEP110,
CEP350, and others. A number of previously uncharacter-
ized proteins were also identified. Note that in addition to
confirming that Flag-BirA*-CEP120 was correctly localized
to the centrosomes, the function of the fusion protein (deter-
mined by its ability to rescue cells inwhich siRNAknockdown
of CEP120 levels led to centriole overduplication) was also
confirmed prior to carrying out BioID. As discussed below
(Section 5), controls of this type have been performed only
rarely in the BioID studies described in this review.
Centrosome duplication occurs once per cell cycle [19]. In
an effort to identify regulators of this process, Firat-Karalar
and Stearns [23] performed BioID on eight proteins in total.
Initially, PLK4 and CEP192 (expressed as Myc-BirA*-PLK4
andMyc-BirA*-CEP192 fusions inHEK293T cells)were used.
The PLK4 and CEP192 proteins are known to interact with
one another but in these experiments BioID was performed
with a non-PLK4-interacting CEP192 isoform. Both fusion
proteins localized correctly to the centrosome in control ex-
periments and expression of the Myc-BirA*-PLK4 protein led
to formation ofmultiple centrioles, indicating that the protein
retains at least some functionality, as a similar phenotype is
seen with wild-type PLK4 expression. Following biotin label-
ing, sucrose gradient centrifugation was used to enrich for
centrosomes prior to protein extraction, streptavidin purifica-
tion, and analysis by MS.
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Among the interactors identified byBioIDwithMyc-BirA*-
PLK4 were CEP152 and CEP192 (both of which had previ-
ously been shown to interact with PLK4 by other methods),
STIL (a protein important for centriole duplication not previ-
ously known to be proximal to PLK4) and various other factors
that had not been implicated previously in centriole duplica-
tion. The list of interactors for Myc-BirA*-CEP192 partially
overlapped that for PLK4 and included the native HEK293
PLK4-interacting isoform of CEP192 itself (implying that the
CEP192 protein is present in multiple copies in the centro-
some) as well as proteins involved in recruitment of PCM
such as NEDD1 and the Aurora kinase AURKA [23].
Following on from this, Firat-Karalar and Stearns [23] ex-
tended their analysis with N-terminal Myc-BirA* fusions of
CEP152, CPAP, CEP63 and theCEP63 paralogueCCDC67, as
well as a C-terminal BirA* fusion of CEP152, reasoning that
the elongated structure of this proteinmight result in spatially
distinct N- and C-terminal interactomes being labeled with
biotin. All five proteins were shown to localize correctly prior
to BioID and the CPAP protein was shown to retain at least
some function, as expression of the Myc-BirA*-CPAP fusion
led to centriole elongation as previously seen with wild-type
CPAP. BioID identified an extensive network of proximal in-
teractions involving these proteins and revealed a previously
unseen connection between centriole duplication proteins
and centriolar satellites, specialized structures that appear to
play a role in protein trafficking to the PCM [23]. Additional
BioID experiments were performed with the CCDC14 and
KIAA0753 proteins to confirm this connection and to probe
further the protein composition of the satellites.
The third BioID study focusing on centrosome biology
is the most comprehensive to be published to date [20]. In
this, 58 proteins were expressed as BirA* fusions for BioID,
including proteins previously found to localize to the centri-
ole (including CEP120, CEP63, and CPAPmentioned above),
to centriolar satellites (including KIAA0753), to centriolar ap-
pendages and to the centrosome-cilium interface. As in pre-
vious studies, the BirA* fusions were stably and inducibly
expressed in HEK293 cells. The resulting interactome map
contains 1700 unique components in a network with >7000
potential interactions. Further investigation of a number of
the previously uncharacterized proteins identified by BioID
confirmed these as novel centrosome, centriolar satellite, or
centriolar appendage components, and systematic functional
analysis of 500 proteins (30% of the interactome) using
siRNA and automated high-resolution microscopy provided
compelling evidence for roles of many of these proteins in
centriole amplification, ciliogenesis, and centriolar satellite
formation.
2.4 Cell junctions
Cell junctions are large multiprotein assemblies that func-
tion to mediate cell–cell and cell–matrix contacts in multicel-
lular organisms. Three major types of cell junctions exist in
mammalian cells: occluding junctions (including tight junc-
tions, see below), communicating junctions, and anchoring
junctions (including adherens junctions).
Three successive BioID studies by Anderson and col-
leagues [24–26] have provided significant insights into the
protein composition and organization of mammalian cell
junctions. Four junction proteins have been used as BirA*
fusions in these studies: ZO-1 [26], E-cadherin [25], occludin,
and claudin-4 [24]. ZO-1 is a tight junction scaffold protein of
>200 kDamolecular mass and a multidomain structure. The
N-terminal half-containing three PDZ domains (responsible
for binding to claudins, ZO-2, and JAM1 proteins, respec-
tively), an SH3 domain, and a guanylate kinase homology
domain that binds to occludin. The C-terminal half-contains
binding sites for actin filaments and the adaptor protein cin-
gulin. For BioID, the human ZO-1 protein was tagged at
N-terminal end to generate aMyc-BirA*-ZO-1 fusion and sep-
arately at the C-terminal end to produce a ZO-1-BirA*-Myc
fusion [26]. Both fusions were stably and inducibly expressed
in MDCK II canine kidney epithelial cells and both colocal-
ized with endogenous canine ZO-1 at tight junctions. BioID
was performed with Myc-BirA* expressing cells as a control
and identified >400 proteins that appear to be proximal to
ZO-1, including a relatively small number of proteins pre-
viously shown to interact with ZO-1 such as actin, cingulin,
occludin, claudin-2 and claudin-3, aswell as a large number of
proteins involved in apparently unrelated cellular processes
or with no known cellular function. Most interactors were
labeled with both N- and C-terminal ZO-1 BirA* fusions but
some were only detected with either the N- or the C-terminal
fusion; others were more abundant when labeled with one
fusion over the other, with the N-terminal Myc-BirA*-ZO-1
fusion labeling a higher number of previously characterized
tight junction proteins and the C-terminal ZO-1-BirA*-Myc
fusion labeling fewer tight junction proteins and a slightly
higher number of cytoskeletal factors [26]. For specific pro-
teins, the pattern of labeling matched expectations based
on previous knowledge of their localization with the N- or
C-terminal halves of ZO-1. Labeling of ZO-2, for example,
which is known to interact with the second of three PDZ
domains in the N-terminal half of ZO-1, was much stronger
with the N-terminal BirA* fusion than the C-terminal one,
underlining the extent to which the BioID method can offer
valuable information on the spatial distribution of proximal
proteins in addition to amore straightforward list of the same.
Following on from their analysis of ZO-1, Anderson and
colleagues have also applied BioID to the cell adhesion pro-
tein E-cadherin [25] and in a separate study, occludin and
claudin-4 [24]. For E-cadherin, the human protein was stably
and inducibly expressed as an N-terminal E-CAD-BirA*-Myc
fusion in MDCK II cells where it was shown to colocalize
with endogenous canine E-cadherin. BioID identified 300
potential E-cadherin proximal proteins, the five most abun-
dant of which (four isoforms of catenin and plakoglobin)
were previously known components of adherens junctions.
Another abundant proteinwas LPP (lipoma-preferred partner
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protein), a member of the zyxin protein family. LPP was also
identified in the ZO-1 screen described in this section, point-
ing to the possibility that it could play roles at both adherens
and tight junctions and prompting a detailed analysis of the
role of this protein in cell function [25].
For occludin (Ocln) and claudin-4 (Cldn4), Anderson and
colleagues [24] stably and inducibly expressed N-terminal
BirA* fusions of both proteins (Myc-BirA*-Ocln and Myc-
BirA*-Cldn4) and a C-terminal Ocln-BirA*-Myc fusion in
MDCK II cells and confirmed their localization to tight junc-
tions and lateral membranes. Consistent with this localiza-
tion, BioID with Ocln and Cldn4 identified numerous tight
junction and lateral membrane proteins, as well as many cell
signaling and trafficking factors and less prominently, pro-
teins with diverse other functions and those with no known
function. Combined with the results obtained with ZO-1 and
E-cadherin [25,26], the Ocln and Cldn4 data [24] provides sig-
nificant insights into the protein composition and organiza-
tion of cell junctions and represents an unparalleled resource
for future investigations.
Two further studies have appeared that apply the BioID
concept to cell junctions, albeit with immunoblotting, rather
than MS, being used to identify proteins labeled by BirA*
[27, 28]. Working with MDCK cells stably expressing a GFP-
BirA*--catenin fusion protein, Yamada and colleagues [27]
took the imaginative approach of performing BioID in cells
subjected to mechanical stretching. Increased biotinylation
of myosin IIA is detected under stretched conditions com-
pared to nonstretched controls, leading to the suggestion that
myosin IIA is recruited to regions of cell–cell contact under
stretched conditions only. Elsewhere, an interaction between
MarvelD3, a transmembrane component of tight junctions,
and the MEKK1 kinase [28] was detected by BioID. BothMyc-
BirA*-MarvelD3 and MarvelD3-BirA*-HA fusions, stably ex-
pressed inMDCK cells, were used in these experiments, with
the interaction being detected by immunoblotting forMEKK1
in biotinylated fractions.
2.5 Autophagy
The TBC1D14 protein is a negative regulator of autophagy
in mammalian cells that associates with members of the
TRAPP (trafficking protein particle) complex. Tooze and col-
leagues [29] adapted the standard BioID strategy to establish
which of the TRAPP components is closest to TBC1D14.
To achieve this, label-free quantitative proteomics (specifi-
cally iBAQ, intensity-based absolute quantification) [30] was
used to quantify TRAPP subunits pulled down from Myc-
BirA*-TBC1D14 cell extracts prepared under denaturing (1%
SDS) and nondenaturing conditions. The results of these
experiments established TRAPPC8 as the most proximal to
TBC1D14 and led to the suggestion that TRAPPC8 mediates
the TBC1D14–TRAPP complex interaction, a proposal that
was confirmed by showing the interaction was disrupted in
TRAPPC8 knockdown cells [29]. To date, this study is alone
in applying a quantitative proteomic approach to BioID data
analysis (discussed further in Section 5).
2.6 Cell signaling pathways
The Hippo pathway plays an important role in controlling
organ size in mammals through regulation of cell prolifera-
tion and apoptosis [31]. The core of the pathway is a protein
kinase cascade. Activation of the pathway causes the MST1
and MST2 kinases to phosphorylate and activate the LATS1
and LATS2 kinases, which then phosphorylate and effectively
inactivate the transcriptional coactivators YAP1 and TAZ1 by
ensuring their retention in the cytosol. When active in the nu-
cleus, YAP1 and TAZ1 function to promote cell proliferation
and inhibit apoptosis.
In order to define the mammalian Hippo interactome,
Gingras and colleagues [32] performed BioID using 19 HeLa
or HEK293 cell lines stably and inducibly expressing differ-
ent Flag-BirA* fusion proteins, including key pathway com-
ponents such as the human MST1, MST2, and LATS1 and
murine Lats2 kinases and the human YAP1 transcription
factor. In total, BioID identified more than 300 proteins as
potential components of theHippo interactome, almost three
times more than were identified in parallel experiments on
a partially overlapping set of 21 Hippo pathway proteins per-
formed by affinity purification [32], with the increased num-
ber of proteins identified by BioID appearing, at least in part,
to reflect the ability of this method to overcome practical
difficulties associated with low protein solubility and weak
protein–protein interactions.
The cerebral cavernous malformation (CCM) complex has
an essential function in cardiovascular development in en-
dothelial cells but how this function is mediated is unclear.
Using BioID Kahn and colleagues [33] established a direct
link betweenCCMand theMEKK3MAPK signaling pathway.
To do this, MEKK3 was expressed from a lentiviral vector as
anHA-BirA*-MEKK3 fusion in human hCMEC/D3 endothe-
lial cells; biotinylated proteins identified by MS included the
CCM complex members CCM2 and KRIT1.
In addition to being useful for studying protein kinases,
BioID has also been used to study phosphoprotein phos-
phatase 2A (PP2A) function in liver metabolism with a view
to identifying factors that interact with the PP2A regulatory
subunit PPP2R5C [34]. In this study, Myc-BirA*-PPP2R5C
and PPP2R5C-BirA*-HA fusions were expressed in mouse
Hepa1-6 cells and biotinylated proteins identified by im-
munoblotting. This study also made use of a cotransfected
catalytically inactive PP2A catalytic subunit in an effort to
trap substrates that otherwise interact only fleetingly with
PPP2R5C.
The calmodulin-like CALML5 protein plays an important
role as a regulator of epidermal differentiation. BioID analysis
using functionally validated BirA*-CALML5 fusion proteins
in differentiated keratinocytes [35] identified a number of
proteins including the 14-3-3 protein stratifin (SFN),
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mutations in which had previously been shown to impair
epidermal differentiation in mice [36,37]. Subsequent BioID
utilizing a BirA*-CALML5 fusion in both normal and
CALML5-depleted differentiated keratinocytes identified a
number of known SFN interactors, including at least one
protein, EXPH5 (exophilin-5), whose interaction with SFN is
reduced in the absence of CALML5, thereby implying a role
for CALML5 in modulating SFN–EXPH5 interactions.
2.7 Nonsense-mediated mRNA decay
Nonsense-mediated decay (NMD) is responsible for the
turnover of mRNA transcripts that contain premature ter-
mination codons in eukaryotic cells [38]. UPF1, UPF2, and
UPF3 are interacting core NMD factors, with the RNA he-
licase UPF1 having a key role in recognition of premature
termination codons. Additional proteins such as the SMG1
kinase, its regulators SMG8 and SMG9, the nuclease SMG6,
and the SMG5-SMG7 heterodimer are then involved in sub-
sequent processing events.
In order to gain greater insight into themachinery ofNMD,
Mu¨hlemann and colleagues [39] performedBioIDwithUPF1,
UPF2, and SMG5 BirA* fusion proteins. Prior to undertak-
ing this work, a comprehensive series of control experiments
were carried out to confirm (i) that BirA* biotinylation oc-
curred exclusively in vivo, prior to cell lysis, (ii) that each
BirA* fusion protein (UPF1, UPF2, SMG5) was able to rescue
the NMD defect of cells in which the corresponding endoge-
nous protein had been depleted by RNA interference, and
(iii) that the activity of the BirA* fusion proteins was com-
parable to that seen with equivalent nonpromiscuous BirA
fusions, indicating that the extensive self-biotinylation of the
BirA* fusion proteins expected during the course of the ex-
periment did not perturb protein function. BioID was then
performed in 293T cells transiently expressing HA-BirA*
fusion proteins, with biotinylated proteins being identified
by immunoblotting and MS. This approach led to the identi-
fication of a number of proteins previously known to interact
closely with UPF1, UPF2, and SMG5, plus range of poten-
tial novel interactors such as the signaling adaptor molecule
CRKL and the heat shock protein DNAJB1, both of which
were biotinylated by all three BirA* fusions but not in the
corresponding controls, as well as mRNA decapping factors
and components of the translation machinery [39].
2.8 Ubiquitin-mediated proteolysis: E3 ligases and
deubiquitylating enzymes
SCF-TrCP1 and SCF-TrCP2 are related ubiquitin E3 ligases that
play key roles in a number of important cell signaling path-
ways (including the Hippo pathway described in the previ-
ous section, but also the Wnt, Hedgehog, and NFB path-
ways) by targeting proteins for proteasomal degradation [40].
Identifying E3 ligase substrates by traditional biochemical
means is particularly challenging as E3 ligase–substrate inter-
actions are often low affinity and/or transient and of course,
result in degradation of the substrate. In their screen for
SCF-TrCP1/2 substrates using BioID, Raught and colleagues
[41] overcame the last of these three problems through the use
of the proteasome inhibitor MG132 to protect ubiquitylated
substrates fromdegradation. The F-box proteins-TrCP1 and
-TrCP2were each stably and inducibly expressed inHEK293
cells as N-terminal Flag-BirA*--TrCP fusions and almost
300 proximal proteins identifiedwithhigh confidence, includ-
ing known components of the SCF-TrCP1/2 complexes such as
SKP1, CUL1, and RBX1 (identified both in the presence and
absence ofMG132, aswould be expected) aswell as previously
identified SCF-TrCP1/2 substrates such as -catenin, claspin,
and the CDC25A and CDC25B phosphatases (identified only
in the presence ofMG132). Further analysis identified almost
80 additional proteins enriched in MG132-treated fractions
as potential SCF-TrCP1/2 substrates, including proteins rep-
resentative of a broad range of functional categories. How
many of these are authentic SCF-TrCP1/2 substrates remains
to be seen, as Coyaud et al. [41] make the important point
that stabilization of an individual substrate that is part of a
larger protein complex (-catenin is one such example) will al-
most certainly lead to increased biotinylation of its interacting
partners.
BioID has also been used as part of wider study by Sanyal
and colleagues [42] to identify deubiquitylating enzymes in-
volved in T-cell receptor signaling in primary T lymphocytes
and their substrates. BioID performed in activated and nonac-
tivated human Jurkat cells using a Myc-BirA*-Usp12 fusion
protein identified a number of potential Usp12 substrates, in-
cluding several proteins previously reported to stabilize T-cell
receptors at the cell surface such as LAT and Trat1 [42].
2.9 Mitochondrial proteasome
The protease ClpP and the AAA+ ATPase ClpX are compo-
nents of the ClpXP proteasome complex [43] that is respon-
sible for the degradation of misfolded proteins in the mam-
malianmitochondrial matrix. To identify potential substrates
of ClpP, Schimmer and colleagues [44] performed BioID in
mitochondria for the first time, stably expressing catalytically
active or inactive BirA*-ClpP fusion proteins in 293 T-REx
cells. Importantly, a BirA* fusion to the unrelated mitochon-
drial matrix protein ornithine transcarbamoylase was used as
a control in these experiments, which ultimately led to the
identification of50 preferential ClpP interactors, including
ClpX and a range of proteins implicated in mitochondrial
metabolism. The demonstration that BioID can, like APEX
[4,5], be applied in the mitochondria opens up a range of pos-
sibilities for future studies of mitochondrial protein function.
2.10 Oncogenic transcription factors
Ewing’s sarcoma is the second most common bone can-
cer in children and young people and is characterized by
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chromosomal translocation events that fuse the gene encod-
ing the EWS protein with one encoding an Ets family tran-
scription factor,most often Fli-1 [45]. The resulting EWS-Fli-1
fusion is an oncoprotein that drives expression of a number
of genes involved in cell proliferation and transformation and
as such is an ideal target for therapeutic intervention [46]. As
part of a study aimed at gaining insights into the biochemical
properties of the EWS-Fli-1 protein, Shiio and colleagues [47]
performed BioID onHEK293T cells that had been transiently
transfected with plasmid expressing a Myc-BirA*-EWS-Fli1-
1 fusion protein. Over 350 potential proximal proteins were
detected by this method. Further experiments confirmed the
interaction of EWS-Fli1-1 with CIMPR, a protein involved
in the endosome-lysosome system, leading to the observa-
tion that EWS-Fli1-1 is turned over by a lysosome-dependent
mechanism and the suggestion that targeting EWS-Fli1-1 for
degradation might be an effective therapy for Ewing’s sar-
coma [47].
Like EWS-Fli-1, c-MYC is an oncogenic transcription fac-
tor. c-MYC regulates the expression of a number of genes,
including genes involved in cell growth, cell cycle progres-
sion, differentiation, and apoptosis, and deregulated c-MYC
expression drives tumor formation [48]. To identify c-MYC
proximal interactors in vivo, Raught and colleagues [49] in-
troduced a plasmid capable of expressing a Flag-BirA*-c-MYC
fusion under the control of a tetracycline-inducible promoter
intoHEK293 cells. The functionality of the Flag-BirA*-c-MYC
protein was assessed in these cells by inducing protein ex-
pression and confirming the ability of the fusion protein to
interact with the c-MYC binding partnerMax and its ability to
activate transcription of the target geneNCL and repress tran-
scription ofCDKN1A. Cells expressing the Flag-BirA*-c-MYC
fusion (or Flag-BirA* alone as a control) were then injected
subcutaneously into immunodeficient NOD/SCID mice. Ex-
pression of the Flag-BirA*-c-MYC fusion was induced by
feeding the animals with tetracycline, resulting in tumor for-
mation. The mice were then injected with biotin over 2 days,
before tumor samples were processed for BioID. For compar-
ison, BioID was also performed on cultured cells expressing
the Flag-BirA*-c-MYC fusion (or Flag-BirA* alone). These
approaches led to the identification of >100 high-confidence
c-MYC proximal interactors present in both cultured cells
and xenografts, including over 30 previously known inter-
actors such as Max [49]. Novel interactors included proteins
involved in, for example, transcription, RNA processing, and
chromatin remodeling.
2.11 Histones H2B and H3
In addition to the chromatin-associated proteins described in
the previous section, BioID has also been applied the core
histones H2B and H3 [50]. To achieve this, the H2B and
H3 proteins were stably expressed in HEK-293 cells as H2B-
and H3-BirA*-Flag fusions. Parental HEK-293 and cell lines
expressing GFP-BirA*-Flag and nuclear localization signal
(NLS)-BirA*-Flag were used as negative controls. Using the
most stringent filtering parameters, 210 interaction partners
were identified for H2B and 90 for H3B, including various
histone chaperones, chromatin remodeling complexes, mi-
totic proteins, etc., with considerable overlap between the two
datasets. These numbers for BioID represent a two to three
times increase in the number of significant interactors for
each protein compared to earlier affinity purification stud-
ies from the same lab [51]. Strikingly, few interactors were
identified by both BioID and affinity purification approaches
(21 out of 210 BioID hits for H2B, ten out of 90 for H3) and
for those proteins identified by both approaches, the evidence
from spectral counts suggests that the different purification
methods favor certain proteins over others. Taking histone
chaperones as an example, CHAF1A/CHAF1B is found with
H3 in greater amounts with BioID than affinity purification,
NAP1L1/NAP1L4 is foundwithH2B in greater amounts with
affinity purification than BioID, and ASF1A/ASF1B is found
with H3 in similar amounts with BioID and affinity purifica-
tion [50]. The reason for this behavior is unclear. However,
it is clear that there is much to be gained from using the
two approaches in parallel, rather than relying on a single
method.
2.12 Mediator
Mediator is a large (30 subunits, >1 MDa) multiprotein
complex that plays an essential role in both initiation and
elongation stages of eukaryotic transcription by bridgingRNA
polymerase II, DNA-binding transcriptional regulators, the
general transcription factors and transcription elongation fac-
tors [52]. Structurally, the Mediator complex comprises four
distinct modules (head, middle, tail, and kinase) whose sub-
unit composition and arrangement with respect to one an-
other has been characterized by a combination of techniques
including cryo-EM and partial crystallography. In addition to
histonesH2B andH3described in Section 2.11, Lambert et al.
[50] performed BioID on three mediator subunits—Med20,
Med4 and Med23, components of the head, middle and tail
modules, respectively—and generated individual HEK-293
cell lines stably expressing C-terminal BirA*-Flag fusions
with these proteins. Parental HEK-293 and GFP-BirA*-Flag
and NLS-BirA*-Flag expressing cell lines were used as nega-
tive controls. BioID of the Med23 and Med4 proteins identi-
fied 25 and 20 Mediator subunits (from all four constituent
structural modules), respectively, as well as a range of other
potential interactors. BioID of Med20 identified six Mediator
subunits only, from themiddle and tailmodules, but it should
be noted that the level of Med20-BirA*-Flag expression was
low, which may explain the low rate of return from this ex-
periment. Interestingly, BioID with Med4 (but not Med20
nor Med23) identified a number of centrosome components
and Lambert et al. [50] were subsequently able to demon-
strate by immunofluorescencemicroscopy that theMed4 pro-
tein colocalizes with the centrosomal markers centrin and
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pericentrin throughout the cell cycle. The biological signifi-
cance of this novel observation remains to be elucidated but
it does underline the power of the BioID approach in uncov-
ering hitherto unexpected connections between proteins. As
with histonesH2B andH3, Lambert et al. [50] also performed
AP-MS (affinity purification followedbyMS) ofMed20,Med4,
andMed23, finding only limited overlap between AP-MS and
BioID datasets and emphasizing once again the importance
of taking multiple experimental approaches to local interac-
tome mapping.
2.13 HMG CoA reductase and Schnyder corneal
dystrophy
Schnyder corneal dystrophy is a human genetic disease that
results in blindness due to a buildup of cholesterol in the
corneas. Schnyder corneal dystrophy is caused by dominant
mutant forms of UBIAD1 (UbiA prenyltransferase domain-
containing protein-1) but how perturbation of UBIAD1 func-
tion leads to cholesterol buildup is unclear. Using BioID,
DeBose-Boyd and colleagues [53] recently demonstrated an
interaction between UBIAD1 and HMG CoA reductase, an
enzyme that catalyzes a rate-limiting step in cholesterol
production in the ER. To do this, the membrane domain
(residues 1–346) of the hamster HMG CoA reductase was ex-
pressed in human HEK293 cells as an HSV-reductase-BirA*
fusion under the control of the cytomegalovirus promoter.
Further analysis revealed thatUBIAD1 binding acts to protect
the reductase from degradation, thus perturbing the normal
control of reductase activity by negative feedback, resulting
in cholesterol accumulation.
3 BioID in unicellular organisms
3.1 Trypanosoma brucei
The unicellular eukaryotic parasite T. brucei is the causative
agent of human African trypanosomiasis (sleeping sickness),
a neglected tropical disease that constitutes a serious health
risk to some 60 million people in sub-Saharan Africa. Three
BioID studies usingT. bruceihave been reported, two ofwhich
[54,55] focused on the biology of the kinetoplastid flagellum,
which plays a vital role in parasite motility.
The first of these studies aimed to characterize the bilobe, a
discrete cytoskeletal structure that partially overlaps with the
flagellum attachment zone (FAZ) at the posterior end of the
cell and in which the TbMORN1 protein is localized. To per-
form BioID on the bilobe, TbMORN1 was stably expressed
as a Myc-BirA*-TbMORN1 fusion protein in procyclic form
T. brucei parasites [55]. The level of Myc-BirA*-TbMORN1 ex-
pression was broadly similar to endogenous TbMORN1 and
the fusion protein localizes to the bilobe, suggesting that a
degree of functionality is retained despite the addition of the
Myc-BirA* sequences. Incubation of Myc-BirA*-TbMORN1
expressing cells with biotin also results in specific labeling
of the bilobe. Twelve biotinylated proteins present in the
detergent-insoluble cytoskeletal fraction were identified by
MS, including TbMORN1 itself, TbLRRP1, known to colo-
calize with TbMORN1, and ten previously uncharacterized
proteins of wholly unknown function. Of these ten, nine
were subsequently shown to colocalize with or be adjacent
to TbMORN1, either as part of the bilobe or FAZ [55].
The second T. brucei BioID study [54] utilized an SAS-4-
BirA*-HA fusion protein, SAS-4 being a component of the
basal body, the structure that nucleates kinetoplastid flagellar
assembly. This study identified 20 putative SAS-4 interac-
tors, including four known FAZ components, three novel
FAZ components, and five proteins that had previously been
identified as novel components of the bilobe by TbMORN1
BioID [55].
The third BioID study in T. brucei [56] focused on the polo-
like kinase homologue TbPLK. This protein localizes to the
basal body, bilobe, FAZ and flagellar connector, and BioID
using Myc-BirA*-TbPLK identified <50 candidate proximal
proteins, many of which associated with these structures,
including five proteins that has previously been identified
in the TbMORN1 screen [55]. The effectiveness of BioID in
T. brucei has the potential to revolutionize the study of this
and related kinetoplastid organisms by offering a simple and
reliable method for forward screens for novel interactors.
3.2 Toxoplasma gondii
Toxoplasma gondii is an obligate intracellular parasite found
in 30–50% of the global population [57]. In healthy adults,
infection with T. gondii is generally asymptomatic, although
mild flu-like symptoms are possible in the first few weeks
after exposure. In immunocompromised individuals, such
as acquired immunodeficiency syndrome (AIDS) patients, or
thoseundergoing treatmentwith immunosuppressant drugs,
infection can result in a more serious disease, even death.
There is an urgent need to understand the biology of the
parasite better with a view to developing effective treatments.
3.2.1 Inner membrane complex
The inner membrane complex (IMC) is a Golgi-derived
double-membrane structure that underlies the plasma mem-
brane, and which is unique to apicomplexan organisms such
as T. gondii and the malaria parasite Plasmodium falciparum
[58]. The IMC plays important roles in motility, host cell in-
vasion, and replication in T. gondii, making it an attractive
target for therapeutic intervention. Some progress has been
made toward defining the protein composition of IMCbut the
nature of the organelle presents challenges to conventional
interactome mapping approaches.
To circumvent these problems, Chen et al. [59] performed
BioID in T. gondii using an ISP3-BirA*-HA fusion protein.
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ISP3 is a key component of the IMC membrane sacs. The
ISP3-BirA*-HA fusion was stably expressed from the ISP3
promoter and localized within the IMC in a manner indis-
tinguishable from the endogenous ISP3 protein. BioID per-
formed on parental and ISP3-BirA*-HA expressing cells in
parallel led to the identification of a number of putative ISP3
interactors, including a number of proteins that had been
previously shown to associate either with IMC membranes
or with the cytoskeletal network underlying the IMC, as well
as uncharacterized proteins. Several of the uncharacterized
proteins were shown by immunofluorescence to localize to
the central and basal subcompartments of the IMCand others
to localize to the apical cap (AC) structure. The AC is involved
in the entry of the parasite into the host cell. To identify addi-
tional AC components, one of these novel proteins (AC2) was
expressed as an AC2-BirA*-HA fusion for BioID, leading to
the identification of several new AC components [59].
3.2.2 TgCDPK3 kinase substrates
TgCDPK3 is a calcium-dependent protein kinase (CDPK)
that is critical for egress of T. gondii parasites from infected
cells and subsequent spread through the infected individ-
ual. To identify potential TgCDPK3 substrates by BioID,
Gaji et al. [60] stably expressed a TgCDPK3-BirA*-HA fu-
sion under the control of the Tgcdpk3 promoter in a Tgcdpk3
mutant strain, allowing them to unambiguously demon-
strate the functionality of the fusion protein in an egress
assay prior to performing biotin labeling. BioID was per-
formed in parallel with a Tgcdpk3 mutant strain expressing
a TgCDPK3-HA fusion protein as control. Fourteen proteins
were detected in the TgCDPK3-BirA*-HA strain, seven of
which, including themyosin A TgMyoA, had previously been
identified as being differentially phosphorylated in wild-type
and Tgcdpk3 mutant cells, underlining their credentials as
TgCDPK3 substrates. Further analysis of TgMyoA phospho-
rylation by TgCDPK3 demonstrated the importance of this
protein for parasite egress. The success of these studies in
T. gondii highlights the applicability of BioID for the explo-
ration of diverse cellular processes in unicellular organisms,
possibly leading to the identification of new therapeutic tar-
gets.
3.3 Dictyostelium discoideum
The amoeba D. discoideum is a widely used model for a va-
riety of cell biological processes, including cellular differen-
tiation, signal transduction, and chemotaxis [61]. As part of
their analysis of the nuclear lamina in D. discoideum, Gra¨f
and colleagues [62, 63] have performed BirA* labeling stud-
ies with the NE81 lamin protein. As discussed previously
(Section 2.1), lamin proteins form insoluble networks under
physiological conditions and so present a significant chal-
lenge to established methods of protein–protein interaction
screening.
To apply themethod toD. discoideum, a BirA*-NE81 fusion
was expressed under the control of the regulatable actin6 pro-
moter, the BirA* ORF having first been codon-optimized to
match the AT-rich nature of D. discoideum coding sequences.
Plasmids expressing the BirA*-NE81 fusion were integrated
in single or multicopy into the D. discoideum genome and
high-level fusion protein expression was induced by growth
in axenic medium. Following purification of biotinylated pro-
teins, immunoblotting revealed proximity labeling by BirA*-
NE81 of endogenous NE81, the lamin-binding protein SUN1
[63], and theMAN1-like protein Src1 [62]. Additional proteins
specifically biotinylated in the presence of BirA*-NE81, but
not in the control cells expressing BirA* alone, were also vi-
sualized in these experiments but as yet no analysis of these
potentially novel interactors has been published.
4 Wider applications of BioID
4.1 Viral infection
Human immunodeficiency virus (HIV) is the causative agent
of AIDS. HIV infects helper T cells (specifically CD4+
T cells), macrophages, and dendritic cells and brings about a
progressive failure of the immune system that results in the
infected individual becoming increasingly susceptible to op-
portunistic infections and cancer. Approximately 40 million
people worldwide are currently living with HIV, mostly in
sub-Saharan Africa, with over 1 million dying per year. The
Gag precursor polyprotein and themature proteins produced
when this is proteolytically processed play important roles at
various points in the HIV-1 replication cycle [64]. Processing
of the Gag precursor yields the matrix (MA), capsid, nucleo-
capsid, and p6 proteins.
In order to better understand the roles of these proteins in
the infection process, two groups have performed indepen-
dent BioID studies on Gag using very different experimental
strategies [65, 66]. Mouland and colleagues [66] took the rela-
tively straightforward route of transiently expressing a Myc-
BirA*-Gag fusion protein in both Jurkat (T lymphocytes) and
HeLa cells. After confirming by immunofluorescence that
the protein was correctly localized, BioID was performed on
Myc-BirA*-Gag expressing Jurkat cells, with cells expressing
Myc-BirA* alone used as a control. This led to the identifica-
tion of 50 proteins proximal to Myc-BirA*-Gag, including
proteins involved in translation and innate immunity. For
two of these proteins (DEAD-box RNA helicase DDX17 and
ribosomal protein S6), interactions were confirmed by coim-
munoprecipitation [66].
In contrast, Barklis and colleagues [65] performed a more
elaborate study that compared data obtained using wild-
type Gag precursor with that from an internally deleted
Gag lacking most of the MA domain. For these experi-
ments, Myc-BirA* was placed between the MA and capsid
domains of the wild-type precursor Gag protein, rather than
at theN-terminal end, and expressed fromproviral expression
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constructs. Around 50 proteins were found to be biotinylated
in cells expressing thewild-type BirA*-Gag protein and/or the
MA-BirA*-Gag version, including translation factors, cy-
toskeletal proteins,membrane proteins, and RNA-processing
factors, over half of which has previously been demonstrated
or implied to interact with HIV-1. Comparison with the data
of Le Sage et al. [66] reveals that only one protein (Lyric/
AEG-1) was found in both screens, presumably reflecting the
different experimental setups.
In addition to analysis of Gag function, BirA* has also been
used as aminor part of an extensive study aimed at dissecting
the role of the Vpu protein in HIV-1 biogenesis [67]. In this
study, Vpu-myc-BirA* was shown to biotinylate the clathrin
adaptor protein AP-1 in 293T cells expressing the host cell
antiviral protein tetherin, which is antagonized by Vpu.
Beyond HIV-1, BioID has also been used to study interac-
tions between the Epstein–Barr virus latent membrane pro-
tein 1 (LMP1) protein and actinin 1 (Actn1) [68]. LMP1 is a
multifunctional membrane protein that is required for estab-
lishment of latent Epstein–Barr virus infection through the
activation of diverse signaling pathways. For BioID experi-
ments, wild-type and mutant forms of LMP1 were expressed
from retroviral vectors in C33A cervical carcinoma cells as
LMP1-BirA* fusions and biotinylated fractions immunoblot-
ted with anti-Actn1 antibodies, leading to the conclusion that
LMP1 interacts with a high molecular weight (potentially
ubiquitylated) isoform of Actn1 [68].
4.2 Bacterial infection
TheGram-negative bacteriumChlamydia psittaci (also known
as Chlamydophila psittaci) is a widely distributed avian
pathogen that can be transmitted to humans to cause a vari-
ety of flu-like symptoms leading to potentially life-threatening
pneumonia [69]. Chlamydia psittaci is an obligate intracellu-
lar parasite. Outside the host cell, C. psittaci cells are found
as metabolically dormant but highly infective particles called
elementary bodies (EBs) that can be taken up into the host
cell by phagocytosis, resulting in the formation of pathogen-
specific organelles called inclusions. Within inclusions, EBs
differentiate to actively replicating but noninfectious particles
known as reticulate bodies (RBs). Mature RBs then differenti-
ate back to EBs which, following release from the host (often
through host cell lysis), go on to infect other cells within the
original host or to be transmitted to other individuals.
The C. psittaci SINC protein is one of a number of effector
proteins that are expressed in the RB and secreted from there
into the host cell cytoplasm, a process that involves transloca-
tion across successive bacterial and endosomal membranes.
Ultimately, SINC enters the nucleus of infected cells where
it localizes to the NE and the INM and nuclear lamina in
particular [70]. Remarkably, SINC localizes to the same sites
in adjacent noninfected cells also, although how this occurs
is unclear as yet.
To better understand the subcellular localization and role
of SINC, Bavoil and colleagues [70] stably expressed a Myc-
BirA*-SINC fusion protein in HEK293 cells for BioID, after
first confirming that the protein localized correctly to the NE
when transiently expressed in HeLa cells. As expected, BioID
identified several INM and nuclear pore proteins, including
lamin B1, lamina-associated protein 1 (LAP1), emerin, and
MAN1, all four of which had previously been identified [6] by
BioID of LaA (discussed in Section 2.1). In total, 50 proteins
proximal to the Myc-BirA*-SINC fusion were identified in
two independent but identical BioID experiments, although
it should be noted that only around half of these were found
in both, including the four mentioned above [70]. The re-
maining high-confidence proximal proteins include factors
involved in nuclear import, ER structure and function, vesicle
trafficking, innate immunity, and signaling, opening up new
avenues of investigation of the role of SINC during C. psittaci
infection.
Biotin labeling by BirA* has also been used to study the
mechanism of host cell protein localization to the inclusion
of a second chlamydial species, Chlamydia trachomatis, the
causative agent of trachoma and the most common bacte-
rial sexually transmitted infection. Moore and colleagues [71]
used BioID in C. trachomatis-infected HeLa cells to demon-
strate that targeting of the host cell SNARE protein syntaxin 6
to the inclusion was dependent on the presence of the signal
sequence YGRL, visualizing full-length and truncated syn-
taxin 6 localization using a fluorescent streptavidin conjugate.
Biotinylated protein pull-down andMS was not performed in
this study [71].
5 Technical considerations
5.1 Design and expression of the BirA* fusion
protein
The starting point for BioID is the expression of a fusion pro-
tein between the protein of interest and the BirA* enzyme.
BirA* has a molecular mass of 35.4 kDa (10 kDa larger
than GFP for example) and is comprised of three distinct
domains, with the active site of the enzyme being located
in the central domain [72, 73]. As described in the previous
sections, both N- and C-terminal BirA* fusions have been
used for BioID studies, with constructs also typically incor-
porating an antibody epitope tag (HA, Myc, or Flag) onto the
distal end of the BirA* protein for convenient immunochem-
ical analysis of fusion protein abundance and localization.
The optimal location (N- or C-terminal) for the attachment
of BirA* will depend on the target protein and for elongated
proteins such as CEP152 or ZO-1 discussed above [21,26], the
spatial specificity of biotin labeling may mean that valuable
additional information can be gained by performing indepen-
dent BioID experiments with N- and C-terminal fusions in
parallel. Under certain circumstances, such as in the anal-
ysis of the HIV-1 Gag precursor protein interactome [65],
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there may also be advantages to placing BirA* internally in
the protein of interest, although this clearly requires prior
knowledge of the domain structure of target protein to en-
sure that BirA* insertion does not disrupt protein structure
and function and potentially invalid the results obtained from
BioID.
Ideally, the BirA* fusion should be expressed in cells at a
similar level to the endogenous target protein, but testing ex-
pression levels normally requires specific antibodies directed
against the target protein, which are not always available.
Even if high levels have no detrimental effects on cell behav-
ior, overproduction of the BirA* fusion protein brings with it
the increased possibility ofmislocalization, nonspecific biotin
labeling, and false positive protein identifications. In most of
the BioID studies on mammalian proteins described in the
previous sections, sequences encoding the BirA* fusion are
stably integrated into the genome of cultured cells (typically
HEK293 or its derivatives) with expression under the control
of a heterologous promoter. Stable integration of the expres-
sion plasmid was also the method of choice for BioID in
T. brucei [55], T. gondii [59, 60], and D. discoideum [63], with
expression of the T. gondii BirA* fusions being driven in both
cases by endogenous promoters. Only in a minority of cases
has BioID been performed following transient cell transfec-
tion (see for example [21, 47]).
For future BioID experiments, a novel endogenous gene
tagging technique for mammalian cells could be utilized
where a multifunctional integrase tag is inserted in-frame
of a gene locus of interest [74]. The tag allows an efficient
recombination-based integration of any functional cassette
by utilizing the Bxb1 integrase enzyme. The developers of
this method used it to perform a BioID study of the proxi-
mal proteome of the epigenetic factor TET1 by inserting the
BirA* cassette into Tet1 locus, such that the BirA*-Tet1 fu-
sion protein was expressed at normal endogenous levels. In
the future, this method would allow physiological conditions
to be maintained during BioID experiments and potentially
detrimental effects due to overexpression of the fusion pro-
tein would be avoided [74].
5.2 Localization and function of the BirA* fusion
Once the appropriate cell line is constructed, it is important
to confirm the subcellular localization of the BirA* fusion
protein by immunofluorescence microscopy with antibodies
raised against either the epitope tag, BirA (anti-BirA antibod-
ies are commercially available from several suppliers) or the
target protein. Correct localization does not guarantee that the
protein of interest will have retained full function, of course,
but whether this is important will depend on the research
question being addressed. If the main aim is to explore the
subcellular environment of the protein of interest, then cor-
rect localization of the fusion protein should be sufficient.
However, if the protein of interest possesses an enzymatic
function that is required for the interactions with the other
proteins, then these interactions will not be detected by BioID
if the protein is inactive. Accordingly, it seemswise to validate
the function of the protein wherever possible. The methods
available to test functionality depend on the protein under
study. In T. gondii for example, BioID with the TgCDPK3-
BirA*-HA fusionwas performed inTgcdpk3mutant cells only
after the function of the fusion protein was tested in a par-
asite egress assay [60], whereas in mammalian cells, BioID
with the Flag-BirA*-CEP120 fusion was performed only after
it was shown that the fusion could rescue the phenotype of
cells treated with a CEP120 siRNA [22]. The latter approach
will be applicable tomany potential BioID targets but whether
it finds wide acceptance in the community remains to be
seen.
5.3 Data analysis
MS data from BioID experiments comprise a large list of po-
tential interactome components. Validating the entire list of
potential interactors may not be feasible, yet certain proteins
have to be selected for further analysis. The studies discussed
in this review have often chosen proteins that were isolated
at highest abundance from MS data. The highest abundance
is a semiquantitative approach and may not reflect the true
strength of association between two proteins [11], but it is an
appropriate starting point.
Perhaps the ideal way to select for high-confidence in-
teractors would be by combining BioID with quantitative
proteomics techniques such as SILAC [75], iTRAQ [76], or
SWATH [77]. Thepower of quantitative proteomics combined
with proximity-dependent labeling is well illustrated by the
APEX studies conducted by Ting and colleagues [4, 5]. These
researchers found that performing SILAC-basedMS inAPEX
experiments allowed elimination of background proteins and
revealed the list of neighboring proteins with higher confi-
dence. Therefore, quantitative proteomics approach is likely
to improve BioID experiments also.
An important step at eliminating nonspecifically biotiny-
lated proteins from BioID experimental results is perform-
ing appropriate controls. The issue of control design has
been extensively discussed by Gingras and colleagues [50]
and will be only briefly mentioned here. Generally, in
the BioID studies performed to date, one of two types
of negative control has been performed, using either the
parental cell line or using cells expressing an epitope-tagged
BirA* protein at the same level as the target protein BirA*
fusion. Lambert et al. [50] themselves trialed a GFP-BirA*-
Flag fusion in their study of the histone H2B and H3 and
Mediator subunit interactomes, as well as NLS-BirA*-Flag
fusion, and reached the conclusion that having multiple
types of control was more useful than having multiple repli-
cates of a single type. The proteins identified from con-
trols could be subtracted from the experimental results to
narrow down to a list of potential interactors with higher
confidence.
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Table 1. Applications of BioID
Section BirA*-tagged proteins Reference
Mammalian cells
2.1 Nuclear lamina LaA [6]
Progerin [16]
Lamin B1 (LMNB1), macroH2A1 [17]
2.2 NPC Nup53 (Nup93 complex component), Nup43,
Nup85, Nup107, Nup133, and Nup160 (all
Y-complex components)
[12]
2.3 Centrosome and
centrosome-cilium interface
CEP120 [22]
PLK4, CEP192, CEP63, CEP152, CPAP, CCDC67,
CCDC14, and KIAA0753.
[21]
58 bait proteins [20]
2.4 Cell junctions ZO-1 [26]
E-cadherin [25]
Occludin, Claudin-4 [24]
MarvelD3 [28]
-catenin [27]
2.5 Autophagy TBC1D14 [29]
2.6 Signaling pathways Hippo pathway: 19 bait proteins [32]
MEKK3 [33]
PPP2R5C [34]
CALML5, SFN [35]
2.7 Nonsense-mediated mRNA
decay
UPF1, UPF2, SMG5 [39]
2.8 Ubiquitin-mediated
proteolysis
-TrCP1, -TrCP2 [41]
Usp12 [42]
2.9 Mitochondrial proteolysis ClpP [44]
2.10 Oncogenic transcription
factors
EWS-Fli-1 fusion protein, c-MYC [47,49]
2.11 Nucleosome Histones H2B and H3 [50]
2.12 Mediator complex Mediator subunits Med4, Med20, Med23 [50]
2.13 Schnyder corneal dystrophy HMG CoA reductase, membrane domain [53]
- Cytokinesis ULK3 (Unc-51-like kinase) [79]
Unicellular organisms
Trypanosoma brucei 3.1 Bilobe/hook complex TbMORN1 [55]
TbSAS-4 [54]
TbPLK [56]
Toxoplasma gondii 3.2 IMC ISP3, AC2 [59]
TgCDPK3 [60]
Dictyostelium discoideum 3.3 Nuclear lamina Lamin NE81 [62,63]
Host-pathogen systems
Viral infection 4.1 HIV-1 Gag polyprotein [65,66]
HIV-1 Vpu [67]
EBV LMP1 [68]
Bacterial infection 4.2 Chlamydia psittaci SINC [70]
Chlamydia trachomatis Syntaxin 6 [71]
EBV: Epstein–Barr virus.
6 Future prospects
One potential obstacle to the application of BioID is the rel-
atively large size (35.4 kDa) of the E. coli BirA* protein. As
noted previously, fusion of BirA* with the target protein can
result in impaired protein localization and function [78]. In an
effort to mitigate this problem, Roux and colleagues [78] in-
vestigated the potential of BirA protein from the thermophilic
bacteriumAquifex aeolicus for BioID studies [78]. TheA. aeoli-
cus protein is the smallest known BirA protein, significantly
shorter than E. coli BirA (223 versus 321 amino acids) and
lacking the latter’s N-terminal DNA binding domain. When
tested in comparison with the standard E. coli BirA* enzyme,
A. aeolicusBirA* (BirA-R40G,where R40G is equivalent to the
promiscuity-conferringR118Gmutation in theE. coliBirA se-
quence) required significantly less biotin for maximal activity
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and allowed better localization of at least one fusion pro-
tein. When fused to the NPC protein Nup43 (see Section 2.2)
in HEK293 cells, the A. aeolicus enzyme appeared to display
enhanced biotinylation activity and a potentially larger la-
beling radius. Increasing the distance between Nup43 and
the A. aeolicus BirA* by linker insertion led to a further
increase in labeling radius without loss of labeling speci-
ficity. It seems highly likely that the A. aeolicus BirA* enzyme
(designed BioID2) will replace the E. coli prototype in future
BioID studies [78].
7 Concluding remarks
In the 4 years from the introduction of BioID [6], the method
has already made significant contributions to mapping local
interactomes relevant to a wide range of biological processes,
both in mammalian cells and in single-celled eukaryotes
(Table 1). The strength of BioID lies in its ability to iden-
tify proteins that interact indirectly or weakly with the protein
of interest or which are located in the vicinity of the protein
of interest without making either a direct or indirect interac-
tion. BioID has also proved especially relevant to the study
of insoluble, inaccessible, or low-abundance structures such
as the nuclear lamina [6], NPC [12], or centrosome [20–22]
and can provide important information on subunit arrange-
ment within large protein assemblies [12]. BioID can also be
used to identify transient protein–protein interactions, such
as those between enzymes and their substrates [32,41]. Taken
together, these attributes guarantee BioID methodology a
vital place in the proteomics toolbox andhighlight its potential
to make continued major contributions to local interactome
mapping in diverse organisms.
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